Psychiatry Investig.
2025 Feb;22(2):130-139. 10.30773/pi.2024.0094.
Association of Rapidly Elevated Plasma Tau Protein With Cognitive Decline in Patients With Amnestic Mild Cognitive Impairment and Alzheimer’s Disease
- Affiliations
-
- 1Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
- 2Center for Geriatrics and Gerontology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
- 3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
- 4Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan
- 5Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- 6Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- KMID: 2564765
- DOI: http://doi.org/10.30773/pi.2024.0094
Abstract
Objective
Whether elevation in plasma levels of amyloid and tau protein biomarkers are better indicators of cognitive decline than higher baseline levels in patients with amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) remains understudied.
Methods
We included 67 participants with twice testing for AD-related plasma biomarkers via immunomagnetic reduction (IMR) assays (amyloid beta [Aβ]1-40, Aβ1-42, total tau [t-Tau], phosphorylated tau [p-Tau] 181, and alpha-synuclein [α-Syn]) and the Mini-Mental State Examination (MMSE) over a 1-year interval. We examined the correlation between biomarker levels (baseline vs. longitudinal change) and annual changes in the MMSE scores. Receiver operating characteristic curve analysis was conducted to compare the biomarkers.
Results
After adjustment, faster cognitive decline was correlated with lower baseline levels of t-Tau (β=0.332, p=0.030) and p-Tau 181 (β=0.369, p=0.015) and rapid elevation of t-Tau (β=-0.330, p=0.030) and p-Tau 181 levels (β=-0.431, p=0.004). However, the levels (baseline and longitudinal changes) of Aβ1-40, Aβ1-42, and α-Syn were not correlated with cognitive decline. aMCI converters had lower baseline levels of p-Tau 181 (p=0.002) but larger annual changes (p=0.001) than aMCI non-converters. The change in p-Tau 181 levels showed better discriminatory capacity than the change in t-Tau levels in terms of identifying AD conversion in patients with aMCI, with an area under curve of 86.7% versus 72.2%.
Conclusion
We found changes in p-Tau 181 levels may be a suitable biomarker for identifying AD conversion.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Correlation between Sleep and C-reactive Protein of Patients in Amnestic Mild Cognitive Impairment and Alzheimer’s Dementia
- The Clinical Significance of Cognitive Interventions for the Patients with Mild Cognitive Impairment
- Tracking Cognitive Trajectories in Mild Cognitive Impairment Using a Machine Learning Technique of Subtype and Stage Inference
- Characteristics of Cognitive Faculties in Elderly Depressive Patientscomplaining of Memory Decline and Patients with Amnestic Mild Cognitive Impairment
- Anti-LGI1 Antibody Limbic Encephalitis Presented with Amnestic Mild Cognitive Impairment
